Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis

Fig. 1

Patient disposition in single ascending dose and multiple ascending dose cohorts. AE adverse event, IV intravenous, MAD multiple ascending dose, RA rheumatoid arthritis, SAD single ascending dose, SC subcutaneous, SLE systemic lupus erythematous

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us